CTOs on the Move

Life Science Services International

www.lssi-us.com

 
Life Science Services International is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.lssi-us.com
  • 6077 Far Hills Ave
    Dayton, OH USA 45459
  • Phone: 937.433.3330

Executives

Name Title Contact Details

Similar Companies

Central Wyoming Counseling Center

Central Wyoming Counseling Center is a non-profit Community Mental Health and Substance Abuse Treatment Center that is dedicated to helping Residents of Wyoming.

Sonovion Pharmaceuticals

Sonovion Pharmaceuticals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medizone International

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets, through its expanding distributor network. The AsepticSure® System is EPA-approved, received the CE mark and is currently pursuing FDA 510(k) registration.

The Buckeye Ranch

Restoring hope and providing healing services for children and families in Central and Southwestern Ohio - from mental health treatment to foster care.

Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.